HBK Investments L P Decreases Position in Bioverativ Inc (BIVV)

HBK Investments L P cut its position in shares of Bioverativ Inc (NASDAQ:BIVV) by 86.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 10,522 shares of the biotechnology company’s stock after selling 67,613 shares during the period. HBK Investments L P’s holdings in Bioverativ were worth $567,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Bioverativ by 16.9% during the fourth quarter. BlackRock Inc. now owns 10,845,635 shares of the biotechnology company’s stock valued at $584,795,000 after purchasing an additional 1,567,638 shares during the last quarter. Old Mutual Global Investors UK Ltd. boosted its position in Bioverativ by 47.8% during the fourth quarter. Old Mutual Global Investors UK Ltd. now owns 2,507,002 shares of the biotechnology company’s stock valued at $135,177,000 after purchasing an additional 810,364 shares during the last quarter. Wells Fargo & Company MN acquired a new position in Bioverativ during the third quarter valued at approximately $124,500,000. Jackson Square Partners LLC boosted its position in Bioverativ by 21.1% during the fourth quarter. Jackson Square Partners LLC now owns 2,107,110 shares of the biotechnology company’s stock valued at $113,615,000 after purchasing an additional 366,503 shares during the last quarter. Finally, OppenheimerFunds Inc. boosted its position in Bioverativ by 147.1% during the fourth quarter. OppenheimerFunds Inc. now owns 1,434,200 shares of the biotechnology company’s stock valued at $77,332,000 after purchasing an additional 853,853 shares during the last quarter. Institutional investors and hedge funds own 97.18% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several research analysts recently commented on the company. William Blair reissued a “hold” rating on shares of Bioverativ in a research report on Thursday, March 8th. Credit Suisse Group reissued a “neutral” rating on shares of Bioverativ in a research report on Wednesday, January 24th. Argus reissued a “hold” rating on shares of Bioverativ in a research report on Wednesday, January 24th. Piper Jaffray Companies cut Bioverativ from an “overweight” rating to a “neutral” rating in a research report on Monday, January 22nd. Finally, Royal Bank of Canada increased their price target on Bioverativ to $68.00 and gave the company a “market perform” rating in a research report on Thursday, January 18th. Twelve equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $63.83.

Shares of Bioverativ Inc (NASDAQ:BIVV) opened at $104.98 on Monday. Bioverativ Inc has a 52-week low of $48.14 and a 52-week high of $105.01. The stock has a market capitalization of $11,360.00 and a P/E ratio of 38.31.

Bioverativ (NASDAQ:BIVV) last released its quarterly earnings data on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.01. Bioverativ had a return on equity of 40.99% and a net margin of 30.43%. The company had revenue of $328.70 million during the quarter, compared to analysts’ expectations of $325.89 million. equities research analysts predict that Bioverativ Inc will post 3.82 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3301603/hbk-investments-l-p-decreases-position-in-bioverativ-inc-bivv.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Karmacoin Price Up 16% Over Last 7 Days
Karmacoin Price Up 16% Over Last 7 Days
Compcoin Hits Market Capitalization of $0.00
Compcoin Hits Market Capitalization of $0.00
United Bitcoin Market Cap Hits $0.00
United Bitcoin Market Cap Hits $0.00
$0.70 EPS Expected for Lakeland Financial Co.  This Quarter
$0.70 EPS Expected for Lakeland Financial Co. This Quarter
New Jersey Resources Co.  Receives Consensus Rating of “Buy” from Brokerages
New Jersey Resources Co. Receives Consensus Rating of “Buy” from Brokerages
Brokerages Set Chico’s  Target Price at $11.10
Brokerages Set Chico’s Target Price at $11.10


© 2006-2018 Ticker Report. Google+.